FDANonrulemakingFDA-2017-D-6821

Providing Comments on CDER Level 2 Guidances

RIN

—

Last modified

Jul 1, 2026

Comment window

—

Association for Accessible Medicines filings

Activity

Association for Accessible Medicines filed 2 comments on this docket between Nov 26, 2021 and Dec 7, 2021. 2 other organizations filed here.

What Association for Accessible Medicines filed (2)

Dec 7, 2021· Comment from Association for Accessible Medicines (AAM)· FDA-2017-D-6821-0015

Comments from the Association for Accessible Medicines (AAM) regarding Docket No: FDA-2017-D-6821: Questions and Answers on Quality Related Controlled Correspondence Guidance for Industry.

View on regulations.gov →

Nov 26, 2021· Comment from Association for Accessible Medicines (AAM) - see FDA-2017-D-6821-0015, guidance was not yet available when submitted· FDA-2017-D-6821-0014

Comments from the Association for Accessible Medicines (AAM) regarding Docket No: FDA-2017-D-6821: Questions and Answers on Quality Related Controlled Correspondence Guidance for Industry.

View on regulations.gov →

Abstract

No abstract recorded.

View on regulations.gov →

Co-filers (2)

See everyone who commented →

Association for Accessible MedicinesTHIS ORG
2 filings · confidence 97%
Consumer Healthcare Products Associationtrade assoc.
1 filing · confidence 97%
Parenteral Drug Associationtrade assoc.
1 filing · confidence 97%